Walleye Capital LLC Cytom X Therapeutics, Inc. Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.41 - $2.74 $120,749 - $234,648	85,638 New	85,638 $186,000
Q2 2022 Aug 08, 2022	SELL	$1.53 - $2.89 $63,548 - $120,036	-41,535 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $110,898 - $194,383	41,535 New	41,535 $111,000
Q2 2021 Aug 16, 2021	SELL	$6.33 - $9.91 $109,793 - $171,888	-17,345 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.6 - $9.0 $114,477 - $156,105	17,345 New	17,345 $134,000
Q1 2020 May 15, 2020	SELL	$3.61 - $8.6 $254,133 - $605,414	-70,397 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $363,952 - $627,237	70,397 New	70,397 $585,000

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.